Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment. NICE technology appraisal guidance 1036
National Institute for Health and Care Excellence (NICE)
Record ID 32018013915
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1036
Year Published:
2025
URL for published report:
https://www.nice.org.uk/guidance/ta1036
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Breast Neoplasms
- Estrogen Receptor alpha
- Receptors, Estrogen
- Tetrahydronaphthalenes
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.